USPTO serial 87190457
ELIXIRGEN
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Oct 31, 2017
- Examiner
- PINO, BRIAN
- Law office
- TMO LAW OFFICE 114
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with ELIXIRGEN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $548*
Plus Government fees of $1,300
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
BALTIMORE, MD, US
Baltimore, MD, US
Baltimore, MD, US
Baltimore, MD, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Leonard D. Bowersox
Leonard D. Bowersox Kilyk & Bowersox, P.L.L.C.3925 Chain Bridge Rd., Suite D-401Fairfax, VA 22030United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | pharmaceutical preparations and substances for the treatment of telomere-shortening diseases (e.g., dyskeratosis congenita, Fanconi anemia, idiopathic and pulmonary fibrosis), karyotype abnormalities (e.g., Down syndrome, and Edwards Syndrome), motor neuron diseases (e.g., Amyotrophic lateral sclerosis, multifocal neuropathy, primary lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, and pseudobulbar palsy), muscular diseases (e.g., Muscular atrophies, muscular growth, myopathy diseases, muscular disorders, muscular dystrophy, myositis, neuromuscular diseases, and sarcopenia), diseases related to the brain, diseases related to the spine, cancer; chemicals and chemical preparations for medical and pharmaceutical purposes for telomere-shortening diseases (e.g., dyskeratosis congenita, and Fanconi anemia), idiopathic pulmonary fibrosis, karyotype abnormalities (e.g., Down syndrome, and Edwards Syndrome), motor neuron diseases (e.g., Amyotrophic lateral sclerosis, multifocal neuropathy, primary lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, and pseudobulbar palsy), muscular diseases (e.g., Muscular atrophies, muscular growth, myopathy diseases, muscular disorders, muscular dystrophy, myositis, neuromuscular diseases, and sarcopenia), diseases related to the brain, diseases related to the spine, and cancers | ACTIVE | May 19, 2016 |
| 042 | Development of pharmaceutical products for others; product quality testing and evaluation for others; research and development of pharmaceutical products for others; research and development of medical products for others | ACTIVE | May 19, 2016 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by ELIXIRGEN THERAPEUTICS, INC.
- Other trademarks owned by Elixirgen, LLC
- Other trademarks owned by Elixirgen, LLC
- Other trademarks owned by Elixirgen, LLC
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named ELIXIRGEN
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 19, 2026 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Jan 30, 2026 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Sep 27, 2023 | NAS8 | NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED | — |
| Sep 27, 2023 | 8.OK | REGISTERED - SEC. 8 (6-YR) ACCEPTED | The USPTO accepted your Section 8 declaration showing the mark is still in use in commerce (or excusable nonuse). This satisfies the six-year maintenance requirement and keeps the registration active until the next renewal deadline. |
| Sep 26, 2023 | EROP | TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED | — |
| Aug 23, 2023 | PRA8 | POST REGISTRATION ACTION MAILED - SEC. 8 | — |
| Aug 22, 2023 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Mar 21, 2023 | ES8R | TEAS SECTION 8 RECEIVED | — |
| Mar 17, 2023 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Mar 17, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 17, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 17, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 17, 2023 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Oct 31, 2022 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Oct 31, 2017 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 15, 2017 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 15, 2017 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 26, 2017 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 12, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 11, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 10, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 10, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 10, 2017 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jan 17, 2017 | GEAN | NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED | — |
| Jan 17, 2017 | GEAP | EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED | — |
| Jan 17, 2017 | EPEN | COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY | — |
| Jan 17, 2017 | CPEA | EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED | — |
| Jan 10, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 7, 2016 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Oct 6, 2016 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 5, 2016 | NWAP | NEW APPLICATION ENTERED | — |